Consumer Narratives in ADR Reporting: An Important Aspect of Public Health? Experiences from Reports to a Swedish Consumer Organization.
作者信息
Vilhelmsson Andreas
机构信息
Division of Social Medicine and Global Health, Department of Clinical Sciences, Faculty of Medicine, Lund University , Malmö , Sweden ; School of Social Work, Faculty of Social Sciences, Lund University , Malmö , Sweden.
出版信息
Front Public Health. 2015 Sep 1;3:211. doi: 10.3389/fpubh.2015.00211. eCollection 2015.
Abstract
摘要
相似文献
1
Consumer Narratives in ADR Reporting: An Important Aspect of Public Health? Experiences from Reports to a Swedish Consumer Organization.
Front Public Health. 2015 Sep 1;3:211. doi: 10.3389/fpubh.2015.00211. eCollection 2015.
2
ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
Drug Saf. 2015 Apr;38(4):337-47. doi: 10.1007/s40264-015-0264-1.
3
Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Health Technol Assess. 2011 May;15(20):1-234, iii-iv. doi: 10.3310/hta15200.
4
How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):37-44. doi: 10.1002/pds.650.
5
Spontaneous adverse drug reaction reporting by patients in Canada: a multi-method study-study protocol.
Springerplus. 2016 Feb 29;5:213. doi: 10.1186/s40064-016-1838-9. eCollection 2016.
6
How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis.
BMC Med Inform Decis Mak. 2016 Mar 1;16:27. doi: 10.1186/s12911-016-0265-8.
7
Monitoring drug safety in Astrakhan, Russia.
Int J Risk Saf Med. 2015;27 Suppl 1:S33-4. doi: 10.3233/JRS-150680.
8
Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
Folia Med (Plovdiv). 2018 Sep 1;60(3):447-453. doi: 10.2478/folmed-2018-0016.
9
Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Eur J Clin Pharmacol. 2015 Jul;71(7):883-90. doi: 10.1007/s00228-015-1867-2. Epub 2015 May 26.
10
Low awareness of adverse drug reaction reporting systems: a consumer survey.
Med J Aust. 2013 Nov 18;199(10):684-6. doi: 10.5694/mja13.10069.
引用本文的文献
1
Estimating Adverse Events Associated With Herbal Medicines Using Pharmacovigilance Databases: Systematic Review and Meta-Analysis.
JMIR Public Health Surveill. 2024 Aug 29;10:e63808. doi: 10.2196/63808.
2
Awareness, Actions, and Predictors of Actions on Adverse Drug Reaction Reporting among Patients Attending a Referral Hospital in Southern Highland Tanzania.
Adv Pharmacol Pharm Sci. 2023 May 9;2023:7761649. doi: 10.1155/2023/7761649. eCollection 2023.
3
Neurologists' Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients-Comparative Analysis from Poland and Egypt.
Int J Environ Res Public Health. 2022 Mar 31;19(7):4169. doi: 10.3390/ijerph19074169.
4
Diabetes patient's pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation.
Ther Adv Drug Saf. 2020 Sep 4;11:2042098620953935. doi: 10.1177/2042098620953935. eCollection 2020.
5
Parental reporting of adverse drug reactions in South Africa: An online survey.
Afr J Prim Health Care Fam Med. 2021 Sep 29;13(1):e1-e8. doi: 10.4102/phcfm.v13i1.2880.
6
Physicians' Understanding and Practices of Pharmacovigilance: Qualitative Experience from A Lower Middle-Income Country.
Int J Environ Res Public Health. 2020 Mar 25;17(7):2209. doi: 10.3390/ijerph17072209.
7
Propensity score-adjusted three-component mixture model for drug-drug interaction data mining in FDA Adverse Event Reporting System.
Stat Med. 2020 Mar 30;39(7):996-1010. doi: 10.1002/sim.8457. Epub 2019 Dec 27.
8
Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial.
Trials. 2018 Mar 9;19(1):174. doi: 10.1186/s13063-018-2560-4.
本文引用的文献
1
Utilizing social media data for pharmacovigilance: A review.
J Biomed Inform. 2015 Apr;54:202-12. doi: 10.1016/j.jbi.2015.02.004. Epub 2015 Feb 23.
2
ADR Reporting by the General Public: Lessons Learnt from the Dutch and Swedish Systems.
Drug Saf. 2015 Apr;38(4):337-47. doi: 10.1007/s40264-015-0264-1.
3
Adverse drug reaction reporting by patients: an overview of fifty countries.
Drug Saf. 2014 Jun;37(6):409-19. doi: 10.1007/s40264-014-0162-y.
4
Low awareness of adverse drug reaction reporting systems: a consumer survey.
Med J Aust. 2013 Nov 18;199(10):684-6. doi: 10.5694/mja13.10069.
5
A Pill for the Ill? Patients' Reports of Their Experience of the Medical Encounter in the Treatment of Depression.
PLoS One. 2013 Jun 18;8(6):e66338. doi: 10.1371/journal.pone.0066338. Print 2013.
6
Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association.
BMC Pharmacol Toxicol. 2012 Dec 23;13:19. doi: 10.1186/2050-6511-13-19.
7
Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
Pharmacoepidemiol Drug Saf. 2012 Oct;21(10):1134-6. doi: 10.1002/pds.3317.
8
Drug safety: reporting systems for the general public.
BMJ. 2012 Aug 7;345:e4916. doi: 10.1136/bmj.e4916.
9
New EU drug safety committee ends national reporting of drug reactions.
BMJ. 2012 Jul 9;345:e4690. doi: 10.1136/bmj.e4690.
10
Newer antidepressants for the treatment of depression in adults.
BMJ. 2012 Jan 19;344:d8300. doi: 10.1136/bmj.d8300.
Zotero 插件